Press monitoring

MPI unblinds prospective study of LungChip prognosticator in early lung cancer

27.11.2015   |   Press monitoring

Hoersholm; November 27, 2015 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that the prospective LungChip study has been unblinded. LungChip is a prognostic tool for predicting which patients have a good or a bad prognosis of their lung cancer, which can have impact on treatment.

Continue


Mission space food: Sugar-growing bacteria go into orbit

27.11.2015   |   Press monitoring

Matt Damon’s character in The Martian has to grow potatoes in his own faeces to survive on Mars. But there may be more appealing ways to make food in space, like using bacteria to make chemicals we can eat, such as sugar. The idea is now set to be put to the test in space for the first time. Genetically modified bacteria will be sent up on a...

Continue


ABLYNX announces nanobody drug discovery collaboration with NOVO NORDISK

25.11.2015   |   Press monitoring

GHENT, Belgium, 25 November 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody ® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to...

Continue


Gene drive mosquitoes engineered to fight malaria

25.11.2015   |   Press monitoring

Mutant mosquitoes engineered to resist the parasite that causes malaria could wipe out the disease in some regions – for good. Humans contract malaria from mosquitoes that are infected by parasites from the genus Plasmodium. Previous work had shown that mosquitoes could be engineered to rebuff the parasite P. falciparum, but researchers lacked a...

Continue


Sanofi and Regeneron Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® (alirocumab) Injection Fully Enrolled

24.11.2015   |   Press monitoring

Paris and Tarrytown, New York - November 24, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential cardiovascular (CV) benefits of Praluent ® (alirocumab) Injection after an acute coronary syndrome...

Continue


Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer

24.11.2015   |   Press monitoring

OXFORD, United Kingdom and PHILADELPHIA, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV...

Continue


Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases

23.11.2015   |   Press monitoring

 Geneva, Switzerland, 23 November 2015 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today that it has been awarded a CHF666,240 grant from the Swiss Commission for Technology and Innovation (CTI) to advance the characterization of allosteric modulator...

Continue


Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis

23.11.2015   |   Press monitoring

Basel, November 23, 2015 - Novartis announced today that the European Commission (EC) has approved Cosentyx ® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor...

Continue


Salmon is first transgenic animal to win US approval for food

23.11.2015   |   Press monitoring

A fast-growing salmon has become the first genetically engineered animal to be approved for human consumption in the United States. The decision, issued by the US Food and Drug Administration (FDA) on 19 November, releases the salmon from two decades of regulatory limbo. The move was met with swift opposition from some environmental and...

Continue


ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis

20.11.2015   |   Press monitoring

Geneva, Switzerland, 20 November 2015 - ObsEva and Kissei Pharmaceutical Co., Ltd. ("Kissei") today announced that they have entered into a collaboration agreement to develop and commercialize KLH-2109 for the treatment of endometriosis and other potential indications. KLH-2109 is a novel, oral gonadotropin-releasing hormone (GnRH) antagonist,...

Continue


 

OPPI, MPO, EU

CEBIO

  • ALIDEA
  • CEBIO
  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina

LinkedIn
TOPlist